Identification of a broad-spectrum arenavirus entry inhibitor

Journal of Virology

Volumn 82, Issue 21, 2008, Pages 10768-10775

  Larson, Ryan A ^a   Dai, Dongcheng ^a   Hosack, Virginia T ^a   Tan, Ying ^a   Bolken, Tove C ^a   Hruby, Dennis E ^a   Amberg, Sean M ^a,b  

^a SIGA Technologies Incorporated   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHOXYPHENYL) N [(4 PROPAN 2 YLPHENYL)METHYL]BENZIMIDAZOL 5 AMINE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; HEXYLRESORCINOL; ST 193; ST 294; ST 761; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARENAVIRUS; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; GENETIC SELECTION; HUMAN; HUMAN CELL; IC 50; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION; VESICULAR STOMATITIS VIRUS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS TYPING; BINDING SITE; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS;

ARENAVIRUS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; VESICULAR STOMATITIS VIRUS;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; ARENAVIRUS; BENZIMIDAZOLES; BINDING SITES; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS; VIRUS INTERNALIZATION;

EID: 55249119582     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00941-08     Document Type: Article

References (57)

1. Agnihothram, S. S., J. York, and J. H. Nunberg. 2006. Role of the stable signal peptide and cytoplasmic domain of G2 in regulating intracellular transport of the Junín virus envelope glycoprotein complex. J. Virol. 80:5189-5198.
2. Agnihothram, S. S., J. York, M. Trahey, and J. H. Nunberg. 2007. Bitopic membrane topology of the stable signal peptide in the tripartite Junín virus GP-C envelope glycoprotein complex. J. Virol. 81:4331-4337.
3. Allison, L. M. C., M. W. A. P. Salter, S. Kiguwa, and C. R. Howard. 1991. Analysis of the glycoprotein gene of Tacaribe virus and neutralization-resistant variants. J. Gen. Virol. 72:2025-2029.
4. Archer, A. M., and R. Rico-Hesse. 2002. High genetic divergence and recombination in arenaviruses from the Americas. Virology 304:274-281.
5. Auperin, D. D., and J. B. McCormick. 1989. Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses. Virology 168:421-425.
6. Barry, M., M. Russi, L. Armstrong, D. Geller, R. Tesh, L. Dembry, J. P. Gonzalez, A. S. Khan, and C. J. Peters. 1995. Treatment of a laboratory-acquired Sabiá virus infection. N. Engl. J. Med. 333:294-296.
7. Bolken, T. C., S. Laquerre, Y. Zhang, T. R. Bailey, D. C. Pevear, S. S. Kickner, L. E. Sperzel, K. F. Jones, T. K. Warren, S. A. Lund, D. L. Kirkwood-Watts, D. S. King, A. C. Shurtleff, M. C. Guttieri, Y. Deng, M. Bleam, and D. E. Hruby. 2006. Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res. 69:86-97.
8. Borio, L., T. Inglesby, C. J. Peters, A. L. Schmaljohn, J. M. Hughes, P. B. Jahrling, T. Ksiazek, K. M. Johnson, A. Meyerhoff, T. O'Toole, M. S. Ascher, J. Bartlett, J. G. Breman, E. M. Eitzen, Jr., M. Hamburg, J. Hauer, D. A. Henderson, R. T. Johnson, G. Kwik, M. Layton, S. Lillibridge, G. J. Nabel, M. T. Osterholm, T. M. Perl, P. Russell, and K. Tonat. 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287:2391-2405.
9. Buchmeier, M. J., J.-C. de la Torre, and C. J. Peters. 2007. Arenaviridae: the viruses and their replication, p. 1791-1827. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 5th ed. Lippincott, Williams and Wilkins, Philadelphia, PA.
10. Cao, W., M. D. Henry, P. Borrow, H. Yamada, J. H. Elder, E. V. Ravkov, S. T. Nichol, R. W. Compans, K. P. Campbell, and M. B. A. Oldstone. 1998. Identification of α-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 282:2079-2081.
11. Centers for Disease Control and Prevention. 2000. Fatal illnesses associated with a New World arenavirus - California, 1999-2000. MMWR Morb. Mortal. Wkly. Rep. 49:709-711.
12. Charrel, R. N., X. de Lamballerie, and C. F. Fulhorst. 2001. The Whitewater Arroyo virus: natural evidence for genetic recombination among Tacaribe serocomplex viruses (family Arenaviridae). Virology 283:161-166.
13. Charrel, R. N., H. Feldmann, C. F. Fulhorst, R. Khelifa, R. de Chesse, and X. de Lamballerie. 2002. Phylogeny of New World arenaviruses based on the complete coding sequences of the small genomic segment identified an evolutionary lineage produced by intrasegmental recombination. Biochem. Biophys. Res. Commun. 296:1118-1124.
14. Delgado, S., B. R. Erickson, R. Agudo, P. J. Blair, E. Vallejo, C. G. Albariño, J. Vargas, J. A. Comer, P. E. Rollin, T. G. Ksiazek, J. G. Olson, and S. T. Nichol. 2008. Chapare virus, a newly discovered arenavirus isolated from a fatal hemorrhagic fever case in Bolivia. PLoS Pathog. 4:e1000047.
15. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
16. Douglas, J. L., M. L. Panis, E. Ho, K.-Y. Lin, S. H. Krawczyk, D. M. Grant, R. Cai, S. Swaminathan, X. Chen, and T. Cihlar. 2005. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 49:2460-2466.
17. Eichler, R., O. Lenz, T. Strecker, M. Eickmann, H.-D. Klenk, and W. Garten. 2003. Identification of Lassa virus glycoprotein signal peptide as a transacting maturation factor. EMBO Rep. 4:1084-1088.
18. Eichler, R., O. Lenz, T. Strecker, M. Eickmann, H.-D. Klenk, and W. Garten. 2004. Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region. J. Biol. Chem. 279:12293-12299.
19. Enria, D. A., and J. I. Maiztegui. 1994. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res. 23:23-31.
20. Eschli, B., K. Quirin, A. Wepf, J. Weber, R. Zinkernagel, and H. Hengartner. 2006. Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins. J. Virol. 80:5897-5907.
21. Fisher-Hoch, S. P., L. Hutwagner, B. Brown, and J. B. McCormick. 2000. Effective vaccine for Lassa fever. J. Virol. 74:6777-6783.
22. Fisher-Hoch, S. P., J. B. McCormick, D. Auperin, B. G. Brown, M. Castor, G. Perez, S. Ruo, A. Conaty, L. Brammer, and S. Bauer. 1989. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc. Natl. Acad. Sci. USA 86:317-321.
23. Fisher-Hoch, S. P., O. Tomori, A. Nasidi, G. I. Perez-Oronoz, Y. Fakile, L. Hutwagner, and J. B. McCormick. 1995. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 311:857-859.
24. Flanagan, M. L., J. Oldenburg, T. Reignier, N. Holt, G. A. Hamilton, V. K. Martin, and P. M. Cannon. 2008. New World clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. J. Virol. 82:938-948.
25. Froeschke, M., M. Basler, M. Groettrup, and B. Dobberstein. 2003. Long-lived signal peptide of lymphocytic choriomeningitis virus glycoprotein pGP-C. J. Biol. Chem. 278:41914-41920.
26. Gallaher, W. R., C. DiSimone, and M. J. Buchmeier. 2001. The viral transmembrane superfamily: possible divergence of Arenavirus and Filovirus glycoproteins from a common RNA virus ancestor. BMC Microbiol. 1:1.
27. Geisbert, T. W., S. Jones, E. A. Fritz, A. C. Shurtleff, J. B. Geisbert, R. Liebscher, A. Grolla, U. Ströher, L. Fernando, K. M. Daddario, M. C. Guttieri, B. R. Mothé, T. Larsen, L. E. Hensley, P. B. Jahrling, and H. Feldmann. 2005. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2:e183.
28. Gonzalez, J. P. J., M. D. Bowen, S. T. Nichol, and R. Rico-Hesse. 1996. Genetic characterization and phylogeny of Sabiá virus, an emergent pathogen in Brazil. Virology 221:318-324.
29. Grande-Pérez, A., G. Gómez-Mariano, P. R. Lowenstein, and E. Domingo. 2005. Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J. Virol. 79:10451-10459.
30. Kilgore, P. E., T. G. Ksiazek, P. E. Rollin, J. N. Mills, M. R. Villagra, M. J. Montenegro, M. A. Costales, L. C. Paredes, and C. J. Peters. 1997. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin. Infect. Dis. 24:718-722.
31. Kondru, R., J. Zhang, C. Ji, T. Mirzadegan, D. Rotstein, S. Sankuratri, and M. Dioszegi. 2008. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol. Pharmacol. 73:789-800.
32. Kunz, S., K. H. Edelmann, J.-C. de la Torre, R. Gorney, and M. B. A. Oldstone. 2003. Mechanisms for lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and incorporation into virions. Virology 314:168-178.
33. Lee, A. M., J. M. Rojek, C. F. Spiropoulou, A. T. Gundersen, W. Jin, A. Shaginian, J. York, J. H. Nunberg, D. L. Boger, M. B. A. Oldstone, and S. Kunz. 2008. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J. Biol. Chem. 283:18734-18742.
34. Maiztegui, J. I., K. T. McKee, Jr., J. G. Barrera Oro, L. H. Harrison, P. H. Gibbs, M. R. Feuillade, D. A. Enria, A. M. Briggiler, S. C. Levis, A. M. Ambrosio, N. A. Halsey, C. J. Peters, and the AHF Study Group. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J. Infect. Dis. 177:277-283.
35. Matthews, T., M. Salgo, M. Greenberg, J. Chung, R. DeMasi, and D. Bolognesi. 2004. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3:215-225.
36. McCormick, J. B., I. J. King, P. A. Webb, K. M. Johnson, R. O'Sullivan, E. S. Smith, S. Trippel, and T. C. Tong. 1987. A case-control study of the clinical diagnosis and course of Lassa fever. J. Infect. Dis. 155:445-455.
37. McCormick, J. B., I. J. King, P. A. Webb, C. L. Scribner, R. B. Craven, K. M. Johnson, L. H. Elliott, and R. Belmont-Williams. 1986. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 314:20-26.
38. McCormick, J. B., P. A. Webb, J. W. Krebs, K. M. Johnson, and E. S. Smith. 1987. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 155:437-444.
39. Naldini, L., U. Blömer, P. Gallay, D. Ory, R. Mulligan, F. H. Gage, I. M. Verma, and D. Trono. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
40. NIAID. 2002. NIAID biodefense research agenda for CDC category A agents. NIH publication no. 03-5308. NIH, Bethesda, MD.
41. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.
42. O'Brien, J., I. Wilson, T. Orton, and F. Pognan. 2000. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur. J. Biochem. 267:5421-5426.
43. Oldenburg, J., T. Reignier, M. L. Flanagan, G. A. Hamilton, and P. M. Cannon. 2007. Differences in tropism and pH dependence for glycoproteins from the clade B1 arenaviruses: implications for receptor usage and pathogenicity. Virology 364:132-139.
44. Radoshitzky, S. R., J. Abraham, C. F. Spiropoulou, J. H. Kuhn, D. Nguyen, W. Li, J. Nagel, P. J. Schmidt, J. H. Nunberg, N. C. Andrews, M. Farzan, and H. Choe. 2007. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446:92-96.
45. Reignier, T., J. Oldenburg, M. L. Flanagan, G. A. Hamilton, V. K. Martin, and P. M. Cannon. 2008. Receptor use by the Whitewater Arroyo virus glycoprotein. Virology 371:439-446.
46. Rojek, J. M., C. F. Spiropoulou, and S. Kunz. 2006. Characterization of the cellular receptors for the South American hemorrhagic fever viruses Junin, Guanarito, and Machupo. Virology 349:476-491.
47. Russmann, S., I. Grattagliano, P. Portincasa, V. O. Palmieri, and G. Palasciano. 2006. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 13:3351-3357.
48. Saunders, A. A., J. P. C. Ting, J. Meisner, B. W. Neuman, M. Perez, J. C. de la Torre, and M. J. Buchmeier. 2007. Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J. Virol. 81:5649-5657.
49. Schrempf, S., M. Froeschke, T. Giroglou, D. von Laer, and B. Dobberstein. 2007. Signal peptide requirements for lymphocytic choriomeningitis virus glycoprotein C maturation and virus infectivity. J. Virol. 81:12515-12524.
50. Sjöberg, M., and H. Garoff. 2003. Interactions between the transmembrane segments of the alphavirus E1 and E2 proteins play a role in virus budding and fusion. J. Virol. 77:3441-3450.
51. Spiropoulou, C. F., S. Kunz, P. E. Rollin, K. P. Campbell, and M. B. A. Oldstone. 2002. New World arenavirus clade C, but not clade A and B viruses, utilizes α-dystroglycan as its major receptor. J. Virol. 76:5140-5146.
52. Sun, Z.-Y. J., K. J. Oh, M. Kim, J. Yu, V. Brusic, L. Song, Z. Qiao, J.-H. Wang, G. Wagner, and E. L. Reinherz. 2008. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-63.
53. York, J., S. S. Agnihothram, V. Romanowski, and J. H. Nunberg. 2005. Genetic analysis of heptad-repeat regions in the G2 fusion subunit of the Junín arenavirus envelope glycoprotein. Virology 343:267-274.
54. York, J., and J. H. Nunberg. 2007. A novel zinc-binding domain is essential for formation of the functional Junín virus envelope glycoprotein complex. J. Virol. 81:13385-13391.
55. York, J., and J. H. Nunberg. 2006. Role of the stable signal peptide of Junín arenavirus envelope glycoprotein in pH-dependent membrane fusion. J. Virol. 80:7775-7780.
56. York, J., V. Romanowski, M. Lu, and J. H. Nunberg. 2004. The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex. J. Virol. 78:10783-10792.
57. York, J., D. Dai, S. M. Amberg, and J. H. Nunberg. 2008. pH-induced activation of arenavirus membrane fusion is antagonized by small-molecule inhibitors. J. Virol. 82:10932-10939.